Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Raul CordobaThibaud PrawitzTracy WestleyAnuj SharmaSumeet AmbarkhaneVenediktos KapetanakisLorenzo SabatelliPublished in: Advances in therapy (2022)
In MAIC analyses, treatment with TAFA + LEN for R/R DLBCL provided better OS and PFS outcomes than standard treatment regimens. Validation from large, randomized, phase 3 clinical trials is required to confirm these results.